HIIFS
NKTR icon

Harel Insurance Investments & Financial Services’s Nektar Therapeutics NKTR Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31
Closed -$26K – 511
2018
Q3 		$26K Sell
31
-2
-6% -$1.71K ﹤0.01% 406
2018
Q2 		$24K Hold
33
– – ﹤0.01% 378
2018
Q1 		$52K Buy
+33
New +$42.5K ﹤0.01% 301

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harel Insurance Investments & Financial Services's NKTR Position: Q4 2018 in Review

Harel Insurance Investments & Financial Services sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 31 shares — an estimated $26K sold.

Harel Insurance Investments & Financial Services first reported a position in NKTR in Q1 2018 and held it in 3 quarters. The position peaked at $52K in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 31 Nektar Therapeutics shares in Q4 2018, an estimated $26K.
  • Harel Insurance Investments & Financial Services first reported a position in Nektar Therapeutics in Q1 2018 and held it in 3 quarters.
  • Harel Insurance Investments & Financial Services's Nektar Therapeutics position peaked at $52K in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2018, filed 29 Jan 2019.